News

In retrospective, observational research at ADA 2024, real-world weight loss was linked to a reduction in the risk of obesity-related cancers.

These data demonstrate a unique dichotomy between 2 trends associated with gender gaps in the field of dermatology.

Atul Malhotra, MD, discusses the results of the SURMOUNT-OSA trial and how they inform clinicians on the role of tirzepatide in OSA and obesity.

New phase 1/2 data suggest VX-880 islet cell therapy may restore physiological islet function and glycemic control in patients with T1D, potentially eliminating the need for insulin use.

Tirzepatide reduces OSA severity by 30 events/hour and achieves remission in up to 51% of patients with obesity, per SURMOUNT-OSA study results from Eli Lilly and Company.

A first-time trial presented at ADA 2024 found the common cholesterol-lowering drug halts vision loss in patients with diabetic eye disease.

Although AAT therapy was found to be well-tolerable, the infusions did not improve C-peptide AUC in patients with chronic pancreatitis undergoing TP-IAT.

Loftus explains the significance of IL-23 and Th17 in IBD and key trial data supporting the FDA approval of risankizumab in ulcerative colitis.

In this systematic review and meta-analysis, the clinical efficacy of glucagon-like peptide 1 receptor agonists was evaluated.

Exposure to carbon monoxide correlated with lower odds of anemia prevalence, whereas exposure to fine particulate matter had the opposite effect.

These data highlight rates of biologic treatment discontinuation in younger adult patients versus elderly patients, with comparisons drawn between IL-23 inhibitors and IL-17 inhibitors as well.

The study APEX-002-B01-02 will evaluate how APEX-52, a microdose psilocybin, can impact safe driving.

Early detection from a universal newborn screening program in Canada significantly reduced disease-related burden in children with SCD.

Positive topline results showed guselkumab (Tremfya) SC induction therapy met all primary and secondary endpoints, suggesting similar clinical benefit to IV induction seen in GALAXI.

These data do not support the idea that interferon-beta works as a trigger for psoriasis, though it may have a different influence on psoriasis among those with MS versus those without MS.

Zerlasiran, a siRNA agent, significantly reduced lipoprotein(a) levels by approximately 90% at 48 weeks in high-risk cardiovascular patients, per phase 2 data from Silence Therapeutics.

Ross-Driscoll explains how disparities in the liver transplant process begin prior to waitlisting and how findings from her research on referral and evaluation may inform interventions.

Genetically predicted anemia may be casually linked to an increased risk of asthma, suggesting its role in the chronic lung disease's development.

This analysis highlights the potential for abrocitinib as an alternative to biologics in the eczema treatment armamentarium.

A survey found individuals may avoid participating in AATD trials because a trial may require them to go off augmentation therapy.

Gish explains recent developments in the treatment of PBC, highlighting the FDA approval of elafibranor, the anticipated decision for seladelpar, and the growing role of combination therapy.

Check out the second quiz in our series testing your knowledge of the ESC/EAS 2019 guidelines on dyslipidemia. This quiz focuses on risk assessment and stratification!

Late-breaking data from EHA 2024 demonstrated a high overall response rate and favorable safety across a range of sHLH patients treated with ELA026.

These data highlight the patterns of treatment as well as prevalence of LPP within the US.

A Mendelian randomization analysis found co-localization between the target genes of SGLT2 inhibitors and the pathogenesis genes of membranous nephropathy and IgAN.

New research from the SOLOST-WHF trial suggests sotagliflozin is a cost-effective treatment for diabetes patients with recent heart failure, with high cost-effectiveness probability.

The approval is based on data from a pair of phase 3 studies and makes risankizumab-rzaa the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn’s disease.

Bitopertin achieves significant reductions in PPIX versus placebo in patients with erythropoietic protoporphyria.